BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Nov 6, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Conjugating ASOs to a GLP-1R agonist construct could enhance the delivery of antisense therapies to pancreatic islet β cells for metabolic diseases. The conjugates consist of 5’-hexylamino ASOs against the selected therapeutic...
BC Innovations | Jul 25, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Zebrafish expressing human PAX3 and FOXO1 could be used to screen therapies for rhabdomyosarcoma. Zebrafish harboring M214K-mutant p53, engineered to express human PAX3 and FOXO1 and injected with a ubiquitous promoter...
BC Innovations | Jul 11, 2018
Translation in Brief

The RNA Renaissance continues

Two papers from Matthew Disney’s lab at The Scripps Research Institute herald a pair of RNA-related discoveries: a method for engineering small molecules that target and cleave oncogenic microRNAs, and a platform that identified RNA-targeting...
BC Innovations | Jun 5, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer An RNA-targeting small molecule that cleaves miR-96 could help treat triple-negative breast cancer (TNBC). The compound consists of a short poly(A) oligionucleotide linked to a small molecule that selectively binds the oncogenic...
BC Extra | Dec 18, 2017
Preclinical News

IL-18 secreting CAR T cells enhance immune killing of tumors

In a paper published in Cell Reports , researchers at the University of Cologne showed that a chimeric antigen receptor (CAR) T cell engineered to release IL-18 converts the CAR T cell to a proinflammatory T...
BC Innovations | Nov 30, 2017
Translation in Brief

Two faces of FOXO1

Columbia University and AstraZeneca plc (LSE:AZN; NYSE:AZN) have identified the first FOXO1 inhibitors that can selectively block the transcription factor’s glucose-stimulating activity without inducing lipogenesis. Optimization of the compounds could yield a therapy for Type...
BC Innovations | Oct 26, 2017
Translation in Brief

Transient nanotargeting

A team from the Fred Hutchinson Cancer Research Center has designed nanoparticles that introduce mRNA cargo to therapeutic cells in vitro , without requiring special instrumentation or causing the cell depletion or cytotoxicity that limits the...
BC Innovations | Oct 24, 2017
Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Nanoparticles; cell therapy Nanoparticles loaded with mRNA could be used for ex vivo programming of patient-derived CAR T cells as cancer therapies. The nanoparticles consist of a biodegradable poly(β-amino ester) polymer core loaded with...
BC Innovations | May 19, 2016
Distillery Therapeutics

Therapeutics: MicroRNA-96 (miR-96)

Cancer INDICATION: Breast cancer In vitro studies identified an miR-96 inhibitor that could help treat breast cancer. In silico drug design and optimization of a benzimidazole-based miR-96 inhibitor identified a heterodimer consisting of the inhibitor...
Items per page:
1 - 10 of 23